Biogen Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
816 / 1361
Position in country
11377 / 14179
Return on Assets, %
4.6
-40.3
Net income margin, %
10.4
-180
EBITDA margin, %
27.3
-168.2
Debt to Equity, %
46.8
3.2
Intangible assets and goodwill, %
54.3
0.2
Revenue CAGR 3Y, %
-9.9
12.5
Total Equity change 1Y, %
10.4
-9
Revenue Y, % chg
-3.4
0
P/E
24.8
31
P/BV
1.9
1.8
P/S
2.9
10.3
EV/S
3.5
7.5
EV/EBITDA
13.6
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
46.8
131.1
Forward P/E
12.3
21.4
Expected dividend per share
0
0
Payout Ratio, %
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Biomarin Pharmaceutical Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
28807.6
Ticker
BIIB.O
ISIN
US09062X1037
IPO date
1991-09-17
Availability on Russian exchanges
Yes
Reporting for
2024-02-14
Date fact. publication of reports
2023-12-31
Company Description
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: